Novo Nordisk interim head of clinical development Michelle Skinner Moore stated that exploring investigational products like CagriSema across the reproductive lifespan is important due to menopausal weight gain

From the articleNovo's next-generation obesity drug shows 25% weight loss in women in late-stage analysisAlso in Novo's CagriSema helped women lose 25% of weight on average, analysis shows | Reuters